Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Texas Oncology Cancer Center Genzyme |
---|---|
Information provided by: | Texas Oncology Cancer Center |
ClinicalTrials.gov Identifier: | NCT00700011 |
The investigators hypothesize that, in addition to its apoptotic effect, clofarabine induces DNA hypomethylation. If the investigators' hypothesis is correct, findings from the present proposal will not only contribute to information relating to the mechanisms of action of clofarabine but also provide the opportunity for combined epigenetic targeting of MDS using clofarabine with either another hypomethylating agent or a histone deacetylase inhibitor.
Clofarabine has demonstrated anti-cancer activity through inhibition of DNA synthesis and repair, induction of apoptosis, and possibly through other mechanisms. Numerous responses have been observed after treatment with clofarabine in heavily pre-treated relapsed/refractory patients with ALL, AML and high risk MDS.
In the present proposal, we will study the clinical and laboratory effects of 2 different dosages of clofarabine in patients who have failed the hypomethylating agent, 5-azacytidine. This study will recruit patients who have received at least six cycles of 5-azacytidine without response or whose disease has progressed or relapsed while on 5-azacytidine. The first cohort of patients will receive clofarabine 10 mg/m2/day for five days and the second cohort of patients 15 mg/m2/day for five days, both every four to six weeks. We will determine the frequency of response to the two dosages of nucleoside analog in this group of patients. Measurement of responses will include improvement in the peripheral blood count, reduction in the blood and platelet transfusion need and eradication of cytogenetically abnormal clones. Successful completion of this study will define the position of clofarabine in MDS in the era of epigenetic targeting.
Condition | Intervention | Phase |
---|---|---|
Myelodysplastic Syndromes |
Drug: Clofarabine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Study of IV Clofarabine for Patients With Myelodysplastic Syndrome Who Have Failed 5-Azacytidine |
Estimated Enrollment: | 20 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | March 2011 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
10 mg/m2
|
Drug: Clofarabine
10 mg/m2 x 5 days per 4 to 6 week cycles
|
2: Active Comparator
15 mg/m2
|
Drug: Clofarabine
15 mg/m2
|
Study Overview
This study will recruit patients who have received at least six cycles of 5-azacytidine without response or whose disease has progressed or relapsed while on 5-azacytidine. The first cohort of patients will receive clofarabine 10 mg/m2/day for five days and the second cohort of patients 15 mg/m2/day for five days, both every four to six weeks. We will determine the frequency of response to the two dosages of nucleoside analog in this group of patients. Measurement of responses will include improvement in the peripheral blood count, reduction in the blood and platelet transfusion need and eradication of cytogenetically abnormal clones.
Primary Objectives
To determine whether clofarabine exhibits a DNA hypomethylating property
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Have adequate renal and hepatic functions as indicated by the following laboratory values:
Exclusion Criteria:
Contact: Seah Lim, MD | 806-358-8654 | seah.lim@usoncology.com |
Contact: John McMahan, RN | 806-358-8654 | john.mcmahan@usoncology.com |
United States, Texas | |
Texas Oncology Cancer Center | Recruiting |
Amarillo, Texas, United States, 79106 | |
Contact: Seah Lim, MD 806-358-8654 seah.lim@usoncology.com | |
Contact: John McMahan, RN 806-358-8654 john.mcmahan@usoncology.com | |
Principal Investigator: Seah Lim, MD |
Principal Investigator: | Seah Lim, MD | Texas Oncology Cancer Center |
Responsible Party: | Texas Oncology Cancer Center ( Seah Lim MD ) |
Study ID Numbers: | iCLO111 |
Study First Received: | June 17, 2008 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00700011 |
Health Authority: | United States: Institutional Review Board |
Myelodysplastic Syndromes |
Clofarabine Myelodysplastic syndromes Preleukemia Precancerous Conditions Hematologic Diseases |
Myelodysplasia Myelodysplastic Syndromes Azacitidine Bone Marrow Diseases |
Neoplasms Pathologic Processes Disease Antineoplastic Agents |
Therapeutic Uses Syndrome Pharmacologic Actions |